XML 81 R18.htm IDEA: XBRL DOCUMENT
v3.25.3

Equity | 9 Months Ended
--- | ---
Sep. 30, 2025
Stockholders' Equity Note [Abstract] |
Equity | EquityStock-Based Compensation Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the AbbVie Amended and Restated 2013 Incentive Stock Program and is summarized as follows:
|  | Three months ended September 30, |  | Nine months ended September 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Cost of products sold |  | $ | 10 |  |  | $ | 12 |  |  | $ | 43 |  |  | $ | 44 |
Research and development |  | 76 |  |  | 67 |  |  | 315 |  |  | 274 |
Selling, general and administrative |  | 123 |  |  | 102 |  |  | 440 |  |  | 429 |
Pre-tax compensation expense |  | 209 |  |  | 181 |  |  | 798 |  |  | 747 |
Tax benefit |  | (35) |  |  | (33) |  |  | (139) |  |  | (127) |
After-tax compensation expense |  | $ | 174 |  |  | $ | 148 |  |  | $ | 659 |  |  | $ | 620 |
In addition to stock-based compensation expense included in the table above and in connection with the 2025 acquisition of Capstan and the 2024 acquisitions of ImmunoGen and Cerevel Therapeutics, AbbVie incurred cash-settled, post-closing expense for employee incentive awards related to these transactions, which is summarized in the table below:
|  | Three months ended September 30, |  | Nine months ended September 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Cost of products sold |  | $ | — |  |  | $ | 5 |  |  | $ | — |  |  | $ | 36 |
Research and development |  | 28 |  | 58 |  | 28 |  | 184
Selling, general and administrative |  | 67 |  | 98 |  | 67 |  | 290
Total post-closing cash settled expense |  | $ | 95 |  |  | $ | 161 |  |  | $ | 95 |  |  | $ | 510 |
Stock Options During the nine months ended September 30, 2025, primarily in connection with the company's annual grant, AbbVie granted 0.6 million stock options with a weighted-average grant-date fair value of $38.39. As of September 30, 2025, $9 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years. RSUs and Performance Shares During the nine months ended September 30, 2025, primarily in connection with the company's annual grant, AbbVie granted 4.9 million RSUs and performance shares with a weighted-average grant-date fair value of $193.72. As of September 30, 2025, $767 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years. Cash Dividends The following table summarizes quarterly cash dividends declared during 2025 and 2024:
2025 |  | 2024
Date Declared |  | Payment Date |  | Dividend Per Share |  | Date Declared |  | Payment Date |  | Dividend Per Share
10/31/25 |  | 02/17/26 |  | $ | 1.73 |  |  | 10/30/24 |  | 02/14/25 |  | $ | 1.64 |
09/05/25 |  | 11/14/25 |  | $ | 1.64 |  |  | 09/06/24 |  | 11/15/24 |  | $ | 1.55 |
06/20/25 |  | 08/15/25 |  | $ | 1.64 |  |  | 06/21/24 |  | 08/15/24 |  | $ | 1.55 |
02/13/25 |  | 05/15/25 |  | $ | 1.64 |  |  | 02/15/24 |  | 05/15/24 |  | $ | 1.55 |
Stock Repurchase Program The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes. On February 16, 2023, AbbVie’s board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization. AbbVie repurchased 3 million shares for $606 million during the nine months ended September 30, 2025 and 5 million shares for $959 million during the nine months ended September 30, 2024. AbbVie's remaining stock repurchase authorization was approximately $2.9 billion as of September 30, 2025. Accumulated Other Comprehensive Loss The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2025:
(in millions) | Foreign currency translation adjustments |  | Net investment hedging activities |  | Pension and post-employment benefits |  |  |  | Cash flow hedging activities |  | Total
Balance as of December 31, 2024 | $ | (2,114) |  |  | $ | 549 |  |  | $ | (664) |  |  |  |  | $ | 304 |  |  | $ | (1,925) |
Other comprehensive income (loss) before reclassifications | 1,489 |  |  | (885) |  |  | 3 |  |  |  |  | (105) |  |  | 502 |
Net losses (gains) reclassified from accumulated other comprehensive loss | — |  |  | (85) |  |  | 2 |  |  |  |  | (68) |  |  | (151) |
Net current-period other comprehensive income (loss) | 1,489 |  |  | (970) |  |  | 5 |  |  |  |  | (173) |  |  | 351 |
Balance as of September 30, 2025 | $ | (625) |  |  | $ | (421) |  |  | $ | (659) |  |  |  |  | $ | 131 |  |  | $ | (1,574) |
Other comprehensive income for the nine months ended September 30, 2025 included foreign currency translation adjustments totaling a gain of $1.5 billion principally due to the impact of the strengthening of the Euro on the translation of the company’s Euro-denominated assets and the offsetting impact of net investment hedging activities totaling a loss of $970 million. The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2024:
(in millions) | Foreign currency translation adjustments |  | Net investment hedging activities |  | Pension and post-employment benefits |  |  |  | Cash flow hedging activities |  | Total
Balance as of December 31, 2023 | $ | (1,106) |  |  | $ | 65 |  |  | $ | (1,488) |  |  |  |  | $ | 224 |  |  | $ | (2,305) |
Other comprehensive income (loss) before reclassifications | 21 |  |  | 31 |  |  | (4) |  |  |  |  | 20 |  |  | 68 |
Net losses (gains) reclassified from accumulated other comprehensive loss | — |  |  | (70) |  |  | 19 |  |  |  |  | (46) |  |  | (97) |
Net current-period other comprehensive income (loss) | 21 |  |  | (39) |  |  | 15 |  |  |  |  | (26) |  |  | (29) |
Balance as of September 30, 2024 | $ | (1,085) |  |  | $ | 26 |  |  | $ | (1,473) |  |  |  |  | $ | 198 |  |  | $ | (2,334) |
The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:
| Three months ended September 30, |  | Nine months ended September 30,
(in millions) (brackets denote gains) | 2025 |  | 2024 |  | 2025 |  | 2024
Net investment hedging activities |  |  |  |  |  |  |
Gains on derivative amount excluded from effectiveness testing(a) | $ | (37) |  |  | $ | (32) |  |  | $ | (108) |  |  | $ | (90) |
Tax expense | 8 |  |  | 7 |  |  | 23 |  |  | 20 |
Total reclassifications, net of tax | $ | (29) |  |  | $ | (25) |  |  | $ | (85) |  |  | $ | (70) |
Pension and post-employment benefits |  |  |  |  |  |  |
Amortization of actuarial losses and other(b) | $ | 2 |  |  | $ | 8 |  |  | $ | 4 |  |  | $ | 25 |
Tax benefit | (1) |  |  | (2) |  |  | (2) |  |  | (6) |
Total reclassifications, net of tax | $ | 1 |  |  | $ | 6 |  |  | $ | 2 |  |  | $ | 19 |
Cash flow hedging activities |  |  |  |  |  |  |
Gains on foreign currency forward exchange contracts(c) | $ | (41) |  |  | $ | (19) |  |  | $ | (69) |  |  | $ | (41) |
Other(a) | (5) |  |  | (6) |  |  | (15) |  |  | (18) |
Tax expense | 8 |  |  | 5 |  |  | 16 |  |  | 13 |
Total reclassifications, net of tax | $ | (38) |  |  | $ | (20) |  |  | $ | (68) |  |  | $ | (46) |
(a) Amounts are included in interest expense, net (see Note 8). (b) Amounts are included in the computation of net periodic benefit cost (see Note 9). (c) Amounts are included in cost of products sold (see Note 8).

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration